

PRODUCT INFORMATION




Montelukast (sodium salt)

Item No. 10008318

CAS Registry No.: 151767-02-1
Formal Name: 1-[[[(1R)-1-[3-(1E)-2-(7-chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]-methyl]-cyclopropaneacetic acid, monosodium salt

Synonym: MK-476
MF: C₃₅H₃₅ClNO₃S • Na
FW: 608.2
Purity: ≥98%
UV/Vis.: λ_{max}: 212, 284, 328, 345, 359 nm
Supplied as: A crystalline solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Montelukast (sodium salt) is supplied as a crystalline solid. A stock solution may be made by dissolving the montelukast (sodium salt) in the solvent of choice, which should be purged with an inert gas. Montelukast (sodium salt) is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide. The solubility of montelukast (sodium salt) in these solvents is approximately 30 mg/ml. It is also soluble in water at a concentration of 10 mg/ml.

Montelukast (sodium salt) is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, montelukast (sodium salt) should first be dissolved in ethanol and then diluted with the aqueous buffer of choice. Montelukast (sodium salt) has a solubility of approximately 0.15 mg/ml in a 1:9 solution of ethanol:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

Montelukast is a cysteinyl leukotriene 1 (CysLT₁) receptor antagonist (IC₅₀ = 4.9 nM in HEK293 cell membranes expressing the human receptor).¹ It is selective for CysLT₁ over CysLT₂ receptors (IC₅₀ = >10,000 nM in COS-7 cell membranes expressing the human receptor).² Montelukast inhibits bronchoconstriction induced by leukotriene D₄ (LTD₄; Item No. 20310) in anesthetized guinea pigs (ED₅₀ = 69 nmol/kg, p.o.).³ It inhibits ovalbumin-induced airway hyperresponsiveness and increases in the number of total cells and eosinophils in bronchoalveolar lavage fluid (BALF) in a mouse model of allergic asthma when administered at doses of 3 and 10 mg/kg.⁴ Formulations containing montelukast have been used in the treatment of asthma, allergic rhinitis, and exercise-induced bronchoconstriction.

References

1. Sarau, H.M., Ames, R.S., Chambers, J., et al. *Mol. Pharmacol.* **56**(3), 657-663 (1999).
2. Heise, C.E., O'Dowd, B.F., Figuerosa, D.J., et al. *J. Biol. Chem.* **275**(39), 30531-30536 (2000).
3. Cabré, F., Carabaza, A., García, A. M., et al. *Eur. J. Pharmacol.* **451**(3), 317-326 (2002).
4. Eum, S. Y., Maghni, K., Hamid, Q., et al. *Am. J. Respir. Cell Mol. Biol.* **28**(1), 25-32 (2003).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 10/12/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM